Citadel Advisors
VCNX

Citadel Advisors’s Vaccinex, Inc. Common Stock VCNX Stock Holding History

Citadel Advisors’s Portfolio VCNX Stock Details VCNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-57
Closed -$4.27K – 15324
2023
Q2 		$4.27K Sell
57
-12
-17% -$999 ﹤0.01% 13611
2023
Q1 		$5.79K Buy
69
+55
+393% +$6.04K ﹤0.01% 13845
2022
Q4 		$1.91K Buy
+14
New +$1.74K ﹤0.01% 14399
2022
Q3 		– Sell
-75
Closed -$17K – 13825
2022
Q2 		$17K Sell
75
-42
-36% -$10.7K ﹤0.01% 12465
2022
Q1 		$32K Buy
117
+56
+92% +$15.5K ﹤0.01% 13075
2021
Q4 		$14K Sell
61
-238
-80% -$85.8K ﹤0.01% 13642
2021
Q3 		$135K Sell
299
-231
-44% -$115K ﹤0.01% 12501
2021
Q2 		$312K Sell
530
-46
-8% -$24.3K ﹤0.01% 11167
2021
Q1 		$361K Buy
576
+424
+279% +$273K ﹤0.01% 10425
2020
Q4 		$66K Buy
+152
New +$63.6K ﹤0.01% 10453

Other funds holding VCNX

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TC
Tacita Capital Toronto, Ontario, Canada $169M AUM 24.7% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citadel Advisors's VCNX Position: Q3 2023 in Review

Citadel Advisors sold out of Vaccinex, Inc. Common Stock (VCNX) in Q3 2023, closing a stake of 491 shares — an estimated $36.7K sold.

Citadel Advisors first reported a position in VCNX in Q3 2020 and held it in 11 quarters. The position peaked at $190K in Q1 2021. 18 funds tracked by Wall St. Rank hold VCNX as of Q3 2023.

  • Citadel Advisors reported no remaining Vaccinex, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Citadel Advisors sold 491 Vaccinex, Inc. Common Stock shares in Q3 2023, an estimated $36.7K.
  • Citadel Advisors first reported a position in Vaccinex, Inc. Common Stock in Q3 2020 and held it in 11 quarters.
  • Citadel Advisors's Vaccinex, Inc. Common Stock position peaked at $190K in Q1 2021.
  • 18 funds tracked by Wall St. Rank held Vaccinex, Inc. Common Stock as of Q3 2023.

Based on Citadel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.